BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 11960341)

  • 1. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
    Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
    Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G; Kantarjian H; Estey E; Thomas D; O'Brien S; Cortes J
    Cancer; 2003 May; 97(9):2218-24. PubMed ID: 12712474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
    Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
    J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia.
    Mayorga J; Richardson-Hardin C; Dicke KA
    Clin J Oncol Nurs; 2002; 6(6):341-6. PubMed ID: 12434466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
    Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
    Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
    N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
    Ghavamzadeh A; Alimoghaddam K; Rostami S; Ghaffari SH; Jahani M; Iravani M; Mousavi SA; Bahar B; Jalili M
    J Clin Oncol; 2011 Jul; 29(20):2753-7. PubMed ID: 21646615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
    Barbey JT; Pezzullo JC; Soignet SL
    J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
    Zhang T; Westervelt P; Hess JL
    Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
    Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
    Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
    Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
    Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
    Grimwade D; Mistry AR; Solomon E; Guidez F
    Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
    Huan SY; Yang CH; Chen YC
    Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
    Shigeno K; Naito K; Sahara N; Kobayashi M; Nakamura S; Fujisawa S; Shinjo K; Takeshita A; Ohno R; Ohnishi K
    Int J Hematol; 2005 Oct; 82(3):224-9. PubMed ID: 16207595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic trioxide, a therapeutic agent for APL.
    Zhang TD; Chen GQ; Wang ZG; Wang ZY; Chen SJ; Chen Z
    Oncogene; 2001 Oct; 20(49):7146-53. PubMed ID: 11704843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.
    Niu C; Yan H; Yu T; Sun HP; Liu JX; Li XS; Wu W; Zhang FQ; Chen Y; Zhou L; Li JM; Zeng XY; Yang RR; Yuan MM; Ren MY; Gu FY; Cao Q; Gu BW; Su XY; Chen GQ; Xiong SM; Zhang TD; Waxman S; Wang ZY; Chen Z; Hu J; Shen ZX; Chen SJ
    Blood; 1999 Nov; 94(10):3315-24. PubMed ID: 10552940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment of relapsed and refractory acute promyelocytic leukemia with arsenic trioxide (As2O3)].
    Tanaka Y; Komatsu H; Ishii K; Nakamura F; Hayashi T; Sawada H; Ono Y; Imanaka T
    Rinsho Ketsueki; 2000 Apr; 41(4):354-7. PubMed ID: 10846468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.